AIM Immunotech Inc. Form 8-K Summary
Business Context and Reporting Period
Company: AIM Immunotech Inc.
Filing Date: June 9, 2026 (Report Date: June 11, 2026)
Event: Entry into a Material Definitive Agreement for a registered direct offering and concurrent private placement.
Location: Ocala, Florida
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Offering Price: $0.5189 per share.
- Registered Direct Offering: 2,554,119 shares of Common Stock.
- Concurrent Private Placement:
- 771,503 shares of Common Stock (Unregistered Shares).
- Pre-Funded Warrants to purchase 1,782,616 shares (Exercise Price: $0.001).
- Class J Warrants to purchase 10,216,476 shares (Exercise Price: $0.5189).
- Expected Gross Proceeds (Immediate): Approximately $1.3 million.
- Potential Additional Proceeds: Approximately $5.3 million if all warrants are exercised for cash.
- Placement Agent Fees: 8.0% cash fee, 0.75% management fee, plus 6.0% of aggregate shares issued as Placement Agent Warrants (306,494 shares).
Material Changes and Unusual Items
The filing reports a significant dilution event and capital structure change:
- Dilution: The issuance of over 10 million Class J Warrant shares represents a substantial potential increase in the share count.
- Liquidity Strategy: The use of Pre-Funded Warrants allows investors to defer cash payment while receiving immediate economic exposure, with the Company receiving minimal immediate cash for these specific instruments.
- Registration Obligations: The Company must file a Form S-1 within 10 days of closing to register the resale of unregistered securities.
Guidance, Outlook, and Risks
Management Commentary: The Company expects the offering to close on or about June 10, 2026. Proceeds are intended for general corporate purposes, though specific allocation is not detailed in this summary.
Risks and Contingencies:
- Uncertainty of Exercise: The Company explicitly states it cannot predict when or if the Pre-Funded Warrants or Class J Warrants will be exercised for cash.
- Stockholder Approval: Class J Warrants are not exercisable until the effective date of stockholder approval of the underlying shares.
- Cashless Exercise: Warrants may be exercised on a cashless basis if no effective registration statement is available at the time of exercise, which would result in no additional cash proceeds to the Company.
Investor Verification Checklist
- Verify the exact closing date and confirmation of the $1.3 million gross proceeds receipt.
- Review the upcoming Form S-1 filing to confirm the registration of unregistered shares and warrants.
- Monitor the schedule for the stockholder meeting required to approve the issuance of Class J Warrant Shares.
- Assess the impact of the 6.0% Placement Agent Warrants and the 10.2 million Class J Warrants on future earnings per share (EPS) and voting control.
- Confirm the Company's cash runway post-offering given the reliance on potential future warrant exercises for the majority of the $5.3 million potential proceeds.